RECRUITING

Access to Genetic Testing in Underserved Patients With Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

Official Title

Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent

Quick Facts

Study Start:2023-10-24
Study Completion:2028-10-24
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06422455

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age \> 18 years old
  2. * Diagnosed with least one of the following:
  3. * Epithelial ovarian cancer
  4. * Exocrine pancreatic cancer
  5. * Metastatic or high or very high-risk prostate cancer
  6. * Breast cancer at or before age 50
  7. * Bilateral breast cancer
  8. * Triple negative breast cancer
  9. * Male breast cancer OR
  10. * Healthcare provider who treats patients with any of the above types of cancer
  11. * Able to read and write in English or Spanish
  12. * Able to provide informed consent
  1. * Patients who cannot provide informed consent
  2. * Patients who cannot see, read, or write
  3. * Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish
  4. * Patients with none of the listed cancer diagnoses and clinical characteristics
  5. * Healthcare provider who do not treats cancer patients

Contacts and Locations

Study Contact

Charite Ricker, MS
CONTACT
323-409-7710
ricker@usc.edu

Principal Investigator

Charite Ricker, MS
PRINCIPAL_INVESTIGATOR
University of Southern California

Study Locations (Sites)

USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
United States
University of Rochester
Rochester, New York, 14642
United States

Collaborators and Investigators

Sponsor: University of Southern California

  • Charite Ricker, MS, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-24
Study Completion Date2028-10-24

Study Record Updates

Study Start Date2023-10-24
Study Completion Date2028-10-24

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Carcinoma
  • Male Breast Carcinoma
  • Malignant Solid Neoplasm
  • Metastatic Prostate Carcinoma
  • Ovarian Carcinoma
  • Pancreatic Exocrine Neoplasm
  • Stage IVB Prostate Cancer American Joint Committee on Cancer v8
  • Triple-Negative Breast Carcinoma